SCHEMBL1883808

SCHEMBL1883808

Cc1ccc(F)c2cc(CO)c(Cl)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
DRD4 P21917 1/20 0.37
DRD3 P35462 1/20 0.37
NPSR1 Q6W5P4 3/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
MAPK1 P28482 2/20 0.34
MAP2K4 P45985 1/20 0.34
MAPKAPK2 P49137 1/20 0.34
MAPKAPK3 Q16644 1/20 0.34
MAPK6 Q16659 1/20 0.34
CD38 P28907 1/20 0.34
IKBKB O14920 1/20 0.33
EPHX2 P34913 1/20 0.32
PRNP P04156 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1880538 0.84 ALDH1A1 (0.43) ALDH1A1KDM4EL3MBTL1DRD4DRD3
SCHEMBL895206 0.80 ALDH1A1 (0.47) ALDH1A1KDM4EL3MBTL1DRD4DRD3
SCHEMBL1728325 0.79 ALDH1A1 (0.41) ALDH1A1KDM4EL3MBTL1DRD4DRD3
SCHEMBL1883632 0.77 GAA (0.42) ALDH1A1KDM4EMAPK1MAP2K4MAPKAPK2
SCHEMBL1885037 0.77 ALDH1A1 (0.46) ALDH1A1KDM4EL3MBTL1DRD4DRD3
SCHEMBL717333 0.73 DRD4 (0.59) ALDH1A1KDM4EL3MBTL1DRD4DRD3
SCHEMBL1725922 0.73 MAPT (0.51) ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6
SCHEMBL5526828 0.72 KDM4E (0.43) ALDH1A1KDM4EL3MBTL1MAPK1RXFP1
SCHEMBL12506963 0.72 ALDH1A1 (0.41) ALDH1A1KDM4ENPSR1MAPK1MAP2K4
SCHEMBL31633211 0.71 KDM4E (0.40) ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399483-B2 Quinoxaline and quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2013-03-19 US disclosed
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA, S.A. (BE) 2011-05-05 US disclosed
EP-2231641-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB Pharma, S.A. (BE) 2010-09-29 EP disclosed
WO-2009081105-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS PDXK, PDPK1, PIKFYVE ALDH1A1 4276/4885KDM4E 2230/4885L3MBTL1 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.